BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305-1314. [PMID: 20066715 DOI: 10.1002/cncr.24884] [Cited by in Crossref: 120] [Cited by in F6Publishing: 116] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Kulik L. Is radioembolization ready for the barcelona clinic liver cancer staging system? Hepatology 2010;52:1528-30. [DOI: 10.1002/hep.24030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Cárdenes HR, Lasley F. Primary Liver Cancer. In: Lo SS, Teh BS, Lu JJ, Schefter TE, editors. Stereotactic Body Radiation Therapy. Berlin: Springer Berlin Heidelberg; 2012. pp. 163-82. [DOI: 10.1007/174_2012_548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017;27:526-35. [PMID: 27277261 DOI: 10.1007/s00330-016-4445-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
4 Kouri BE, Abrams RA, Al-Refaie WB, Azad N, Farrell J, Gaba RC, Gervais DA, Gipson MG, Kolbeck KJ, Marshalleck FE, Pinchot JW, Small W Jr, Ray CE Jr, Hohenwalter EJ. ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. J Am Coll Radiol 2016;13:265-73. [PMID: 26944037 DOI: 10.1016/j.jacr.2015.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Huang M, Lin Q, Wang H, Chen J, Bai M, Wang L, Zhu K, Jiang Z, Guan S, Li Z, Qian J, Li M, Pang P, Shan H. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26:3428-3436. [PMID: 26792430 DOI: 10.1007/s00330-015-4198-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
6 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Manas D, Bell JK, Mealing S, Davies H, Baker H, Holmes H, Hubner RA. The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. Eur J Surg Oncol 2021;47:401-8. [PMID: 32958370 DOI: 10.1016/j.ejso.2020.08.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21:294-302. [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
9 Zhao J, Zhang H, Wei L, Xie S, Suo Z. Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison. Oncotarget 2017;8:15101-13. [PMID: 27835871 DOI: 10.18632/oncotarget.13145] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
10 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
11 Cucchetti A, Cappelli A, Ercolani G, Mosconi C, Cescon M, Golfieri R, Pinna AD. Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies. Liver Cancer. 2016;5:303-311. [PMID: 27781202 DOI: 10.1159/000449341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
12 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [DOI: 10.1002/hep.23725] [Cited by in Crossref: 323] [Cited by in F6Publishing: 320] [Article Influence: 26.9] [Reference Citation Analysis]
13 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
14 Pillai AA, Ramanathan M, Kulik L. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis 2020;24:681-700. [PMID: 33012453 DOI: 10.1016/j.cld.2020.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kalva SP, Pectasides M, Yeddula K, Ganguli S, Blaszkowsky LS, Zhu AX. Factors Affecting Survival following Chemoembolization with Doxorubicin-eluting Microspheres for Inoperable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2013;24:257-65. [DOI: 10.1016/j.jvir.2012.10.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Ni JY, Xu LF, Wang WD, Sun HL, Chen YT. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2014; 20(45): 17206-17217 [PMID: 25493037 DOI: 10.3748/wjg.v20.i45.17206] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
17 Merle P, Mornex F. [Nonsurgical management of hepatocellular carcinoma]. Cancer Radiother 2010;14:469-73. [PMID: 20739209 DOI: 10.1016/j.canrad.2010.07.228] [Reference Citation Analysis]
18 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
19 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, Pracht M, Raoul JL, Clément B, Garin E. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518-2525. [PMID: 23494107 DOI: 10.1245/s10434-013-2906-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
21 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
22 Carr BI. Hepatic artery chemoembolization for hepatocellular carcinoma recurrence confined to the transplanted liver. Case Rep Oncol. 2012;5:506-510. [PMID: 23139662 DOI: 10.1159/000343043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
23 Pancoska P, Carr BI, Branch RA. Network-based analysis of survival for unresectable hepatocellular carcinoma. Semin Oncol 2010;37:170-81. [PMID: 20494709 DOI: 10.1053/j.seminoncol.2010.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
24 Ludwig JM, Zhang D, Xing M, Kim HS. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. Eur Radiol 2017;27:2031-41. [PMID: 27562480 DOI: 10.1007/s00330-016-4548-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
25 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
26 Yang B, Liang J, Qu Z, Yang F, Liao Z, Gou H. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS One 2020;15:e0227475. [PMID: 32074102 DOI: 10.1371/journal.pone.0227475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
27 Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
28 Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:421673. [PMID: 22655206 DOI: 10.5402/2012/421673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
29 Kouri BE, Funaki BS, Ray CE, Abou-Alfa GK, Burke CT, Darcy MD, Fidelman N, Greene FL, Harrison SA, Kinney TB. ACR Appropriateness Criteria radiologic management of hepatic malignancy. J Am Coll Radiol. 2012;9:919-925. [PMID: 23206650 DOI: 10.1016/j.jacr.2012.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
30 Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016;39:1580-1588. [PMID: 27586657 DOI: 10.1007/s00270-016-1426-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
31 Kovács A, Iezzi R, Cellini F, Lancellotta V, Bischoff P, Carchesio F, Tagliaferri L, Kovács G, Gambacorta MA. Critical review of multidisciplinary non-surgical local interventional ablation techniques in primary or secondary liver malignancies. J Contemp Brachytherapy 2019;11:589-600. [PMID: 31969919 DOI: 10.5114/jcb.2019.90466] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
32 Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144. [PMID: 22913492 DOI: 10.1186/1745-6215-13-144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
33 Zhang ZF, Luo YJ, Lu Q, Dai SX, Sha WH. Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new? World J Clin Cases 2018; 6(9): 259-273 [PMID: 30211206 DOI: 10.12998/wjcc.v6.i9.259] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
35 Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, Kim BK, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Int J Radiat Oncol Biol Phys 2017;99:396-406. [PMID: 28871990 DOI: 10.1016/j.ijrobp.2017.05.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
36 Kan RW, Tsang SH, Poon RT, Cheung TT. Update on yttrium-90-based radio-embolization for treatment of hepatocellular carcinoma. ANZ J Surg. 2012;82:505-509. [PMID: 22747591 DOI: 10.1111/j.1445-2197.2012.06121.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Riaz A, Kulik LM, Mulcahy MF, Lewandowski RJ, Salem R. Yttrium-90 radioembolization in the management of liver malignancies. Semin Oncol. 2010;37:94-101. [PMID: 20494701 DOI: 10.1053/j.seminoncol.2010.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
38 Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. Journal of Hepatology 2012;56:464-73. [DOI: 10.1016/j.jhep.2011.07.012] [Cited by in Crossref: 173] [Cited by in F6Publishing: 175] [Article Influence: 17.3] [Reference Citation Analysis]
39 Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22:1697-1705. [PMID: 21983055 DOI: 10.1016/j.jvir.2011.08.013] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
40 Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepat Med 2010;2:147-55. [PMID: 24367212 DOI: 10.2147/HMER.S7123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
41 Kim DY, Han KH. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 2016;10:883-92. [PMID: 27126821 DOI: 10.1007/s12072-016-9722-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
42 Hawkins CM, Kukreja K, Geller JI, Schatzman C, Ristagno R. Radioembolisation for treatment of pediatric hepatocellular carcinoma. Pediatr Radiol 2013;43:876-81. [PMID: 23212597 DOI: 10.1007/s00247-012-2568-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
43 Lanza E, Donadon M, Poretti D, Pedicini V, Tramarin M, Roncalli M, Rhee H, Park YN, Torzilli G. Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer 2016;6:27-33. [PMID: 27995085 DOI: 10.1159/000449347] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
44 Carr BI, Guerra V, Steel JL, Lu SN. A comparison of patients with hepatitis B- or hepatitis C-based advanced-stage hepatocellular carcinoma. Semin Oncol. 2015;42:309-315. [PMID: 25843735 DOI: 10.1053/j.seminoncol.2014.12.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
45 Milgrom DP, Maluccio MA, Koniaris LG. Management of Hepatocellular Carcinoma (HCC). Curr Surg Rep 2016;4. [DOI: 10.1007/s40137-016-0143-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
46 Lv WF, Han JK, Cheng DL, Zhou CZ, Ni M, Lu D. CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers. Korean J Radiol 2015;16:810-20. [PMID: 26175580 DOI: 10.3348/kjr.2015.16.4.810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
47 Khalaf H, Alsuhaibani H, Al-sugair A, Al-mana H, Al-mutawa A, Al-kadhi Y, Al-sebayel M. Use of Yttrium-90 Microsphere Radioembolization of Hepatocellular Carcinoma as Downstaging and Bridge Before Liver Transplantation: A Case Report. Transplantation Proceedings 2010;42:994-8. [DOI: 10.1016/j.transproceed.2010.03.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
48 Yoneoka G, Bozhilov K, Wong LL. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma. Hepatoma Res 2020;6:67. [PMID: 33134551 DOI: 10.20517/2394-5079.2020.57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Akinwande O, Kim D, Edwards J, Brown R, Philips P, Scoggins C, Martin RC 2nd. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol. 2015;24:270-275. [PMID: 26133576 DOI: 10.1016/j.suronc.2015.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
50 Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36:714-723. [PMID: 23093355 DOI: 10.1007/s00270-012-0481-2] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
51 Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016;12:1193-204. [PMID: 27007495 DOI: 10.2217/fon-2016-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yang Y, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Biol Med 2018;15:299-310. [PMID: 30197797 DOI: 10.20892/j.issn.2095-3941.2017.0177] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
53 Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7:72343-72355. [PMID: 27579537 DOI: 10.18632/oncotarget.11644] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
54 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
55 She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, Liu RK, Poon RT, Chan SC, Fan ST, Lo CM. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014;3:185-193. [PMID: 25202695 DOI: 10.3978/j.issn.2304-3881.2014.07.09] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
56 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
57 Sanoff HK, Chang Y, Stavas JM, Stürmer T, Lund J. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. J Natl Compr Canc Netw 2015;13:1102-10. [PMID: 26358794 DOI: 10.6004/jnccn.2015.0135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
58 Ventura Y, Carr BI, Kori I, Guerra V, Shibolet O. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. World J Gastroenterol 2018; 24(15): 1641-1649 [PMID: 29686471 DOI: 10.3748/wjg.v24.i15.1641] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012;138:455-62. [DOI: 10.1007/s00432-011-1117-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
60 Finn RS, Zhu AX, Farah W, Almasri J, Zaiem F, Prokop LJ, Murad MH, Mohammed K. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology. 2018;67:422-435. [PMID: 28881497 DOI: 10.1002/hep.29486] [Cited by in Crossref: 77] [Cited by in F6Publishing: 88] [Article Influence: 19.3] [Reference Citation Analysis]
61 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
62 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
63 van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev 2016;:CD010181. [PMID: 27486906 DOI: 10.1002/14651858.CD010181.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
64 Parikh ND, Cuneo K, Mendiratta-Lala M. Radiation Therapies for the Treatment of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:341-6. [PMID: 34136139 DOI: 10.1002/cld.1060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Carr BI, Metes DM. Peripheral Blood Lymphocyte Depletion After Hepatic Arterial 90Yttrium Microsphere Therapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2012;82:1179-84. [DOI: 10.1016/j.ijrobp.2010.10.042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
66 Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 2013;57:1826-37. [DOI: 10.1002/hep.26014] [Cited by in Crossref: 290] [Cited by in F6Publishing: 268] [Article Influence: 32.2] [Reference Citation Analysis]
67 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
68 Carr BI. Some new approaches to the management of hepatocellular carcinoma. Semin Oncol 2012;39:369-73. [PMID: 22846855 DOI: 10.1053/j.seminoncol.2012.05.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
69 Bozkurt MF, Salanci BV, Uğur Ö. Intra-Arterial Radionuclide Therapies for Liver Tumors. Seminars in Nuclear Medicine 2016;46:324-39. [DOI: 10.1053/j.semnuclmed.2016.01.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
70 Talenfeld AD, Sista AK, Madoff DC. Transarterial therapies for primary liver tumors. Surg Oncol Clin N Am. 2014;23:323-351. [PMID: 24560113 DOI: 10.1016/j.soc.2013.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
71 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33:327-337. [PMID: 23331661 DOI: 10.1111/liv.12083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
72 Sangro B, D'avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2011;12:1057-73. [DOI: 10.1517/14656566.2011.545346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
73 Saxena A, Meteling B, Kapoor J, Golani S, Danta M, Morris DL, Bester L. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients. Int J Surg. 2014;12:1403-1408. [PMID: 25091398 DOI: 10.1016/j.ijsu.2014.07.269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
74 Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [PMID: 25126539 DOI: 10.3389/fonc.2014.00199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
75 Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P, Frenette C. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015;6:469-78. [PMID: 26487939 DOI: 10.3978/j.issn.2078-6891.2015.056] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
76 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Tao R, Li X, Ran R, Xiao Z, Zhang H, Kong H, Song Q, Huang Y, Wang L, Huang J. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget 2017;8:5460-73. [PMID: 27705924 DOI: 10.18632/oncotarget.12348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311-318. [PMID: 23615394 DOI: 10.1159/000348325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 10.1] [Reference Citation Analysis]
79 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
80 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
82 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
83 Carr BI, Guerra V. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Dig Dis Sci 2016;61:937-47. [PMID: 26576554 DOI: 10.1007/s10620-015-3922-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
84 Kwon JH, Kim GM, Han K, Won JY, Kim MD, Lee DY, Lee J, Choi W, Kim YS, Kim DY, Han KH. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cardiovasc Intervent Radiol. 2018;41:459-465. [PMID: 29067511 DOI: 10.1007/s00270-017-1826-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8(9): 421-438 [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 14.2] [Reference Citation Analysis]
86 Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:207-224. [PMID: 22941023 DOI: 10.1007/978-3-642-16037-0_14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
87 Li Z, Bonekamp S, Halappa VG, Corona-Villalobos CP, Pawlik T, Bhagat N, Reyes D, Lai H, Geschwind JF, Kamel IR. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology. 2012;264:97-109. [PMID: 22627602 DOI: 10.1148/radiol.12112161] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
88 Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: Should treatment be expanded? Dig Liver Dis. 2010;42 Suppl 3:S258-S263. [PMID: 20547312 DOI: 10.1016/s1590-8658(10)60514-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
89 Rana N, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, Lee JS. Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib. Front Oncol. 2013;3:323. [PMID: 24416722 DOI: 10.3389/fonc.2013.00323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
90 Rostambeigi N, Dekarske AS, Austin EE, Golzarian J, Cressman EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:1075-1084. [PMID: 24861664 DOI: 10.1016/j.jvir.2014.04.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
91 Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent? Cardiovasc Intervent Radiol 2020;43:721-31. [PMID: 32140840 DOI: 10.1007/s00270-020-02434-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Chung Y, Han G, Yoon J, Yang J, Wang J, Shao G, Kim BI, Lee T, Chao Y. Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013;132:2448-58. [DOI: 10.1002/ijc.27925] [Cited by in Crossref: 53] [Cited by in F6Publishing: 66] [Article Influence: 5.3] [Reference Citation Analysis]
93 Gui B, Weiner AA, Nosher J, Lu SE, Foltz GM, Hasan O, Kim SK, Gendel V, Mani NB, Carpizo DR, Saad NE, Kennedy TJ, Zuckerman DA, Olsen JR, Parikh PJ, Jabbour SK. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. Am J Clin Oncol. 2018;41:861-866. [PMID: 28418940 DOI: 10.1097/coc.0000000000000384] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
94 Gutierrez JA, Gish RG. Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res 2013;2:460-71. [PMID: 26504748 DOI: 10.3978/j.issn.2218-676X.2013.10.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
95 Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, Qi F, Zhao C. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol. 2012;29:2992-2997. [PMID: 22200992 DOI: 10.1007/s12032-011-0145-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
96 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
97 Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Corti A, Tredici M, Piccinno M, Giorgi L, Bartolozzi C, Bargellini I. Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World J Gastroenterol 2015; 21(21): 6518-6525 [PMID: 26074690 DOI: 10.3748/wjg.v21.i21.6518] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
98 Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N; Comité de l'évolution des pratiques en oncologie. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford) 2015;17:52-65. [PMID: 24961288 DOI: 10.1111/hpb.12273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
99 Zaidi A, Ahmed S, Ahmed S, Brunet B, Davies J, Doll C, Dueck DA, Gordon V, Hebbard P, Kim C, Le D, Lee-Ying R, Lim H, Liu D, McGhie JP, Mulder K, Park J, Renouf D, Schellenberg D, Wong RPW, Moser M. Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC. Curr Oncol 2021;28:4317-27. [PMID: 34898545 DOI: 10.3390/curroncol28060367] [Reference Citation Analysis]
100 Hsieh TC, Wu YC, Sun SS, Yen KY, Kao CH. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. Biomedicine (Taipei). 2016;6:19. [PMID: 27848114 DOI: 10.7603/s40681-016-0019-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
101 Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, Eggenhoffner R, Bresci G, Cabibbo G, Giacomelli L. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:25-9. [PMID: 27574589 DOI: 10.2147/JHC.S50359] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
102 Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology 2017;66:338-46. [DOI: 10.1016/j.jhep.2016.09.008] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 28.8] [Reference Citation Analysis]
103 Fidelman N, Kerlan RK Jr. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease. AJR Am J Roentgenol 2015;205:742-52. [PMID: 26397322 DOI: 10.2214/AJR.15.14802] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
104 Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group). Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35:1036-1047. [PMID: 24750853 DOI: 10.1111/liv.12574] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
105 Buckstein M, Kim E, Fischman A, Blacksburg S, Facciuto M, Schwartz M, Rosenzweig K. Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2018;9:734-40. [PMID: 30151270 DOI: 10.21037/jgo.2018.05.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
106 Golfieri R. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepat Oncol 2014;1:265-83. [PMID: 30190962 DOI: 10.2217/hep.14.6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
107 Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015;4:16-25. [PMID: 26020026 DOI: 10.1159/000343878] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
108 Chu KKW, Cheung TT. Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol 2015; 7(11): 1562-1571 [PMID: 26085915 DOI: 10.4254/wjh.v7.i11.1562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
109 Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013;45:712-23. [DOI: 10.1016/j.dld.2013.01.012] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
110 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
111 Molvar C, Lewandowski RJ. Intra-Arterial Therapies for Liver Masses. Radiologic Clinics of North America 2015;53:973-84. [DOI: 10.1016/j.rcl.2015.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
112 Raoul JL, Edeline J, Pracht M, Boucher E, Rolland Y, Garin E. [Radioembolisation for hepatocellular carcinoma]. Cancer Radiother 2011;15:64-8. [PMID: 21236718 DOI: 10.1016/j.canrad.2010.12.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
113 Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, Rowe I, Hodgson R, Eastwood A. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technol Assess 2020;24:1-264. [PMID: 33001024 DOI: 10.3310/hta24480] [Reference Citation Analysis]
114 James T, Hill J, Fahrbach T, Collins Z. Differences in Radiation Activity Between Glass and Resin 90Y Microspheres in Treating Unresectable Hepatic Cancer. Health Phys 2017;112:300-4. [PMID: 28121731 DOI: 10.1097/HP.0000000000000631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
115 Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol 2016; 8(18): 770-778 [PMID: 27366304 DOI: 10.4254/wjh.v8.i18.770] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
116 Negm O, Abou Saif S, El Gharib M, Yousef M, Abd-Elsalam S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2017;29:317-21. [PMID: 27893491 DOI: 10.1097/MEG.0000000000000790] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
117 Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011;28 Suppl 1:S286-90. [PMID: 21107755 DOI: 10.1007/s12032-010-9750-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
118 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol 2015; 7(11): 1553-1561 [PMID: 26085914 DOI: 10.4254/wjh.v7.i11.1553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
119 Cai B, Altman MB, Garcia-Ramirez J, LaBrash J, Goddu SM, Mutic S, Parikh PJ, Olsen JR, Saad N, Zoberi JE. Process improvement for the safe delivery of multidisciplinary-executed treatments-A case in Y-90 microspheres therapy. Brachytherapy 2017;16:236-44. [PMID: 27618420 DOI: 10.1016/j.brachy.2016.08.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
120 Bauschke A, Altendorf-Hofmann A, Freesmeyer M, Winkens T, Malessa C, Schierz JH, Teichgraeber U, Settmacher U. [Selective internal radioembolization in nonresectable hepatocellular carcinoma]. Chirurg 2016;87:956-63. [PMID: 27460230 DOI: 10.1007/s00104-016-0259-1] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]